Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Skye Bioscience, Inc. (SKYE : NSDQ)

• Company Description    Skye Bioscience Inc. is a biopharmaceutical company. It is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Skye Bioscience Inc., formerly known as Emerald Bioscience Inc., is based in San Diego, Calif. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $0.62 Daily Weekly Monthly 20 Day Moving Average: 1,137,980 shares Shares Outstanding: 33.38 (millions) Market Capitalization: $20.86 (millions) Beta: 2.86 52 Week High: $5.75 52 Week Low: $0.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.20% -10.88% 12 Week -14.03% -9.57% Year To Date -16.63% -12.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11250 EL CAMINO REAL SUITE 100 - SAN DIEGO,CA 92130 USA ph: 858-410-0266 fax: - ir@skyebioscience.com http://www.skyebioscience.com

• General Corporate Information    Officers Punit Dhillon - Chief Executive Officer Paul Grayson - Chairman Deborah Charych - Director Andrew J. Schwab - Director Karen Smith - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 83086J200 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/14/26 Share - Related Items Shares Outstanding: 33.38 Most Recent Split Date: 9.00 (0.00:1) Beta: 2.86 Market Capitalization: $20.86 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.00 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -50.00% vs. Previous Quarter: -12.50% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - -143.59 09/30/25 - -100.49 06/30/25 - -76.03 ROA 12/31/25 - -119.89 09/30/25 - -88.69 06/30/25 - -69.20 Current Ratio 12/31/25 - 3.30 09/30/25 - 4.77 06/30/25 - 6.09 Quick Ratio 12/31/25 - 3.30 09/30/25 - 4.77 06/30/25 - 6.09 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - 0.62 09/30/25 - 1.06 06/30/25 - 1.41 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©